Injection site reactions (ISRs) are reactions that occur at the site of injection of a drug. They may be mild or severe and may or may not require medical intervention. Some reactions may appear immediately after injection, and some may be delayed. Such reactions can occur with subcutaneous, intramuscular, or intravenous administration. Drugs commonly administered subcutaneously include local anesthetics, drugs used in palliative care (e.g., fentanyl and morphine), and biopharmaceuticals (e.g., vaccines, heparin, insulin, growth hormone, hematopoietic growth factors, interferons, and monoclonal antibodies).

Signs and symptoms

Some reactions, such as pain, may appear immediately. Others may be delayed, such as erythema which may appear 24–96 hours after injection. ISRs commonly seen with subcutaneous injections include: Severe reactions may result in cutaneous necrosis at the injection site, typically presenting in one of two forms: (1) those associated with intravenous infusion or (2) those related to intramuscular injection. Intramuscular injections may produce a syndrome called livedo dermatitis.

Causes

There are many factors that can affect incidence of injection site reactions. They may be related to the drug formulation itself, to the method of injection, or to the patient. Some factors such as volume of injection and speed of injection seem to not be well correlated with incidence of reaction.

Product-related factors

Injection-related factors

Features of the needle used for injection can affect ISRs:

Patient-related factors

Mechanism

The exact mechanism of various reactions differs, and not all reactions are allergic or immunogenic. In some cases there is inflammatory influx, consistent with leukocytoclastic vasculitis (e.g. infiltrating neutrophils, prominent nuclear dust, lymphocytes and eosinophils with local macrophage infiltration). There may be evidence of subcutaneous fat tissue necrosis.

Prevention

Adequate patient education and training on correct procedure for self-administration can lower the incidence rate of reactions. Rotating injection sites, proper sterilization, and allowing the medication to reach room temperature before injection can help prevent ISRs. Applying a cold compress after the injection may be helpful. When possible, decreasing the frequency of administration may help. Premedication with antihistamines or corticosteroids does not seem to prevent ISRs.

Treatment

In some cases, reactions and their severity may diminish with subsequent administrations of the drug. For non-severe reactions, common approaches include: For severe reactions, discontinuation of the medication and acute medical treatment of the reaction may be required.

Prognosis

Epidemiology

For many biologics (e.g., monoclonal antibodies), injection site reactions are the most common adverse effect of the drug, and have been reported to have an incidence rate of 0.5–40%. In trials of subcutaneous administration of oligonucleotides, between 22 and 100% of subjects developed reactions depending on the oligonucleotide.